Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country
Patients with lower risk MDS, including MDS 5q-, may benefit from treatment with erythropoiesis stimulating agent (ESA). Patients with higher risk MDS may have a favorable outcome with decitabine (HMA) treatment.
Authors
- Minh Phuong Vu (ORCID: https://orcid.org/0000-0001-5473-557X)
- Nguyen Hao Quang (ORCID: https://orcid.org/0000-0003-0622-0859)
- Ha Thanh Nguyen (ORCID: https://orcid.org/0000-0002-1545-6495)
- Duc Binh Vu
- Quoc Khanh Bach
- Ha Trang Kieu
Institutions
- Hanoi Medical University (VN)
- Thai Nguyen National General Hospital (VN)
- Bạch Mai Hospital (VN)
Publication Details
- Journal
- Leukemia Research Reports
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.lrr.2024.100490
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00